^
    almost3years
    ACLX-002, a novel CD123-targeted universal CAR-T cell therapy for relapsed or refractory acute myeloid leukemia that can be activated and silenced in vivo with soluble protein adapters in a dose dependent manner (AACR 2022)
    Furthermore, the in vivo efficacy was not limited by the expression of CD123 on donor T cells, an attribute that is induced by in vitro activation and expansion of ARC-T cells. The data support the paradigm that ARC-T cells can be activated and silenced by controlling the dose and schedule of administered SPRX002, which may improve the safety and effectiveness of T cell therapy.
    Preclinical • CAR T-Cell Therapy • IO biomarker
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 expression
    |
    ACLX-002